LINC01697: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01697

NCBI ID: G284825

LINC01697

Other Name(s): Long intergenic non-protein coding RNA 1697, transcript variant 1 | long intergenic non-protein coding RNA 1697

LINC01697: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC01697 is a long non-coding RNA (lncRNA) with a length of approximately 291 nucleotides. It is found in the genomic region between exons 18 and 19 of the X chromosome in humans. LINC01697 is not a protein, but it does encode a protein-like structure domain, which is similar to those of known non-coding RNAs that play important roles in gene regulation and development.

The discovery and characterization of LINC01697

The LINC01697 gene was first identified by bioinformatic analysis of transcriptomic data from the X chromosome of human beings. The gene is located in the distal region of the X chromosome and is close to the gene silencing element hotspot region on the X chromosome[ 3].

To further study the function of LINC01697, researchers used RNA sequencing (RNA-seq) to identify its expression patterns in various tissues and cellular types. The results showed that LINC01697 was highly expressed in the brain, heart, and tests, and was also expressed in other tissues and organs, including the liver, muscle, and placenta.

The structure and function of LINC01697

The structure of LINC01697 was determined using bioinformatic analysis of its cDNA sequence. The analysis revealed that LINC01697 has a conserved core structure, which includes a variable region, a stem-loop region, and a terminal region that contains a putative RNA binding domain (RBS) and a conserved tail domain (TTS).

The conserved core structure of LINC01697 is similar to that of other non-coding RNAs that encode proteins or RNA binding proteins. The RBS and TTS regions are commonly found in non-coding RNAs and are involved in protein-RNA interactions, which are important for protein function and development.

In addition to the conserved core structure, LINC01697 also contains a highly conserved region at its 5' end, which includes a uniqueGUGTTG repeat. The repeat sequence is conserved across different species and has been shown to play important roles in gene regulation and RNA function.

The function of LINC01697

The function of LINC01697 is currently being investigated as a potential drug target and biomarker. Several studies have shown that LINC01697 is involved in various cellular processes, including cell growth, apoptosis, and inflammation.

One potential mechanism by which LINC01697 may be involved in cancer development is its role in cell proliferation. LINC01697 has been shown to promote the growth of various cancer cell types, including breast, ovarian, and colorectal cancer.

Another potential mechanism by which LINC01697 may be involved in cancer progression is its role in cell apoptosis. LINC01697 has been shown to promote the apoptosis of various cell types, including cancer cells.

In addition to its potential role in cancer development, LINC01697 may also be involved in other cellular processes that are important for overall health and disease. For example, LINC01697 has been shown to be involved in inflammation, which is a complex process that can contribute to various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

The potential utility of LINC01697 as a drug target or biomarker

The results of the studies described above suggest that LINC01697 may be a promising drug target or biomarker for a variety of diseases. LINC01697 has been shown to be involved in

Protein Name: Long Intergenic Non-protein Coding RNA 1697

The "LINC01697 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01697 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets